Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Moodys
Colorcon
AstraZeneca
Baxter

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR VOSORITIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Vosoritide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02055157 ↗ A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia Completed BioMarin Pharmaceutical Phase 2 2014-01-13 This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
NCT02724228 ↗ A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) Active, not recruiting BioMarin Pharmaceutical Phase 2 2016-01-26 This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.
NCT03197766 ↗ A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Completed BioMarin Pharmaceutical Phase 3 2016-12-12 The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.
NCT03424018 ↗ An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Active, not recruiting BioMarin Pharmaceutical Phase 3 2017-12-12 The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
NCT03583697 ↗ A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia Active, not recruiting BioMarin Pharmaceutical Phase 2 2018-05-23 Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vosoritide

Condition Name

Condition Name for Vosoritide
Intervention Trials
Achondroplasia 6
Short Stature 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vosoritide
Intervention Trials
Achondroplasia 6
Dwarfism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vosoritide

Trials by Country

Trials by Country for Vosoritide
Location Trials
United States 47
Australia 10
United Kingdom 6
Japan 4
Spain 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vosoritide
Location Trials
Texas 6
Illinois 6
California 6
Wisconsin 4
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vosoritide

Clinical Trial Phase

Clinical Trial Phase for Vosoritide
Clinical Trial Phase Trials
Phase 3 2
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vosoritide
Clinical Trial Phase Trials
Active, not recruiting 3
Completed 2
Enrolling by invitation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vosoritide

Sponsor Name

Sponsor Name for Vosoritide
Sponsor Trials
BioMarin Pharmaceutical 6
Andrew Dauber 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vosoritide
Sponsor Trials
Industry 6
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Dow
Moodys
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.